{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"34.0","value":"34.6"},{"groupId":"OG001","spread":"41.4","value":"33.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"115"},{"groupId":"OG001","value":"85"}],"units":"Participants"}],"title":"7-day post-infusion AUC (AUC(d0-7)) - Cycle 1, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"43.8","value":"31.3"},{"groupId":"OG001","spread":"46.0","value":"26.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"63"}],"units":"Participants"}],"title":"AUC(d0-7) - Cycle 1, Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"36.7","value":"36.4"},{"groupId":"OG001","spread":"30.0","value":"32.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"72"}],"units":"Participants"}],"title":"AUC(d0-7) - Cycle 2, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"41.2","value":"35.9"},{"groupId":"OG001","spread":"35.8","value":"27.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"56"}],"units":"Participants"}],"title":"AUC(d0-7) - Cycle 2, Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"44.7","value":"34.7"},{"groupId":"OG001","spread":"47.5","value":"30.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"59"}],"units":"Participants"}],"title":"14-day post-infusion AUC (AUC(d0-14)) - Cycle 1, Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"40.4","value":"41.2"},{"groupId":"OG001","spread":"36.6","value":"33.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"60"}],"units":"Participants"}],"title":"AUC(d0-14) - Cycle 2, Day 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"120"},{"groupId":"OG001","value":"87"}],"units":"Participants"}],"description":"AUC was derived from the PK blood samples collected.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants in Cohort 1 had received prior treatment with platinum-containing chemotherapy. Enfortumab vedotin, at a dose of 1.25 mg/kg, was administered to participants as an IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle.","id":"OG000","title":"Enfortumab Vedotin - Cohort 1"},{"description":"Participants in Cohort 2 had received no platinum-containing chemotherapy were ineligible for treatment with cisplatin at the time of enrollment. Enfortumab vedotin, at a dose of 1.25 mg/kg, was administered to participants as an IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle.","id":"OG001","title":"Enfortumab Vedotin - Cohort 2"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK analysis set: all participants who received enfortumab vedotin and from whom at least one blood sample was collected and assayed for enfortumab vedotin, monomethyl auristatin E (MMAE) or total antibody (Tab) concentration. Corresponding records of the time of dosing and sample collection must also be available for all enfortumab vedotin. Here, 'Number Analyzed'= participants evaluable at specified timepoints.","reportingStatus":"POSTED","timeFrame":"AUC0-7 was assessed (in cycles 1 and 2) based on concentration data from Day 1 to Day 8 (pre dose) and AUC0-14 was assessed based on data from D15 (pre dose) to D29 (pre-dose)","title":"PK Parameter for Enfortumab Vedotin: Area Under Concentration-Time Curve (AUC) (Serum)","type":"SECONDARY","unitOfMeasure":"Day*microgram per milliliter"}